Treatment of Drug-Resistant Tuberculosis
American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, Infectious Diseases Society of AmericaPublished: January 28, 2020
- Key Points
- Summary of Good Practices
- Treatment Recommendations
- For the selection of an effective MDR-TB treatment regimen and duration of MDR-TB treatment
- For the selection of oral drugs for MDR-TB treatment
- For selected oral drugs previously included in regimens for the treatment of MDR-TB
- For the selection of drugs administered through injection when needed to compose an effective treatment regimen for MDR-TB
- For the use of the WHO-recommended standardized shorter-course 9–12 month regimen for MDR-TB
- For the role of surgery in the treatment of MDR-TB
- For the treatment of isoniazid-resistant TB
- For the management of contacts to patients with MDR-TB
- Tables
- Summary of Recommendations on Drugs for Use in a Treatment Regimen for Patients with MDR-TB, Including Strength of Recommendation, Certainty in the Evidence and Relative Effects on Death and Treatment Success
- Clinical Strategy to Build an Individualized Treatment Regimen for MDR-TB
- Doses of Drugs for Treatment of Adults and Children with MDR-TB
- Select Antiretroviral and Non–rifamycin-based Anti-tuberculosis Drug Overlapping Toxicities and Potential Adverse Drug-drug Interactions
Also Found In
You rely on Guideline Central for transparency
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.